ASX - By Stock
|
PER |
Re:
Ann: Notification regarding unquoted securities - PER
|
|
Vinceanna
|
43 |
7.2K |
15 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
43
|
7.2K
|
15
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
Vinceanna
|
33 |
9.4K |
27 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
33
|
9.4K
|
27
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
Vinceanna
|
971 |
242K |
27 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
971
|
242K
|
27
|
|
ASX - By Stock
|
PER |
Re:
Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
|
|
Vinceanna
|
127 |
32K |
12 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
127
|
32K
|
12
|
|
ASX - By Stock
|
PER |
Re:
Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
|
|
Vinceanna
|
127 |
32K |
47 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
127
|
32K
|
47
|
|
ASX - By Stock
|
PER |
Re:
Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
|
|
Vinceanna
|
127 |
32K |
20 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
127
|
32K
|
20
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
Vinceanna
|
157 |
36K |
28 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
157
|
36K
|
28
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase IIb study of ATL1102 in DMD completes recruitment
|
|
Vinceanna
|
102 |
27K |
38 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
102
|
27K
|
38
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
Vinceanna
|
971 |
242K |
27 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
971
|
242K
|
27
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase IIb study of ATL1102 in DMD completes recruitment
|
|
Vinceanna
|
102 |
27K |
18 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
102
|
27K
|
18
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase IIb study of ATL1102 in DMD completes recruitment
|
|
Vinceanna
|
102 |
27K |
40 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
102
|
27K
|
40
|
|
ASX - By Stock
|
PER |
Re:
PER - Megathread
|
|
Vinceanna
|
326 |
104K |
19 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
326
|
104K
|
19
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
25 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
25
|
|
ASX - By Stock
|
PER |
Re:
Ann: Annual General Meeting Presentation
|
|
Vinceanna
|
81 |
21K |
16 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
81
|
21K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Reject Name Change Resolution
|
|
Vinceanna
|
43 |
13K |
31 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
43
|
13K
|
31
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
17 |
21/10/23 |
21/10/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
17
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
Vinceanna
|
1.0K |
306K |
14 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
1.0K
|
306K
|
14
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
Vinceanna
|
1.0K |
306K |
19 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
1.0K
|
306K
|
19
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
15 |
25/09/23 |
25/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
15
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics Corporate Presentation
|
|
Vinceanna
|
82 |
23K |
34 |
12/09/23 |
12/09/23 |
ASX - By Stock
|
82
|
23K
|
34
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
Vinceanna
|
190 |
50K |
49 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
190
|
50K
|
49
|
|
ASX - By Stock
|
PER |
Re:
Ann: Intention to launch Share Purchase Plan
|
|
Vinceanna
|
75 |
21K |
16 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
75
|
21K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Ann: Institutional Placement and proposed Share Purchase Plan SPP
|
|
Vinceanna
|
71 |
19K |
15 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
71
|
19K
|
15
|
|
ASX - By Stock
|
PER |
Re:
Fresh Start
|
|
Vinceanna
|
105 |
29K |
14 |
18/03/23 |
18/03/23 |
ASX - By Stock
|
105
|
29K
|
14
|
|
ASX - By Stock
|
PER |
Re:
Fresh Start
|
|
Vinceanna
|
105 |
29K |
9 |
18/03/23 |
18/03/23 |
ASX - By Stock
|
105
|
29K
|
9
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
4 |
04/01/23 |
04/01/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics CEO announces retirement
|
|
Vinceanna
|
204 |
68K |
13 |
16/11/22 |
16/11/22 |
ASX - By Stock
|
204
|
68K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: Long Covid-19 Collaboration Outcomes Presentation
|
|
Vinceanna
|
228 |
86K |
22 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
228
|
86K
|
22
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
18 |
12/08/22 |
12/08/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
18
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
19 |
06/08/22 |
06/08/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
19
|
|
ASX - By Stock
|
PER |
Re:
Ann: Proteomics and disease marker identification in DMD Webinar
|
|
Vinceanna
|
25 |
8.3K |
10 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
25
|
8.3K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: Proteomics and disease marker identification in DMD Webinar
|
|
Vinceanna
|
25 |
8.3K |
13 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
25
|
8.3K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to Present at the PPMD Annual Conference 2022
|
|
Vinceanna
|
88 |
22K |
9 |
26/06/22 |
26/06/22 |
ASX - By Stock
|
88
|
22K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Presentation at 2nd Annual Oligonucleotide for CNS Summit
|
|
Vinceanna
|
19 |
6.5K |
7 |
25/06/22 |
25/06/22 |
ASX - By Stock
|
19
|
6.5K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to Present at the PPMD Annual Conference 2022
|
|
Vinceanna
|
88 |
22K |
6 |
25/06/22 |
25/06/22 |
ASX - By Stock
|
88
|
22K
|
6
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
13 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
|
|
Vinceanna
|
86 |
23K |
12 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
86
|
23K
|
12
|
|
ASX - By Stock
|
PER |
Re:
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
|
|
Vinceanna
|
86 |
23K |
10 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
86
|
23K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
|
|
Vinceanna
|
86 |
23K |
25 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
86
|
23K
|
25
|
|
ASX - By Stock
|
PER |
Re:
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
|
|
Vinceanna
|
86 |
23K |
24 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
86
|
23K
|
24
|
|
ASX - By Stock
|
PER |
Re:
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
|
|
Vinceanna
|
86 |
23K |
26 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
86
|
23K
|
26
|
|
ASX - By Stock
|
PER |
Re:
Ann: Long COVID-19 strategic collaboration with US Experts
|
|
Vinceanna
|
245 |
70K |
14 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
245
|
70K
|
14
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
23 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
23
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
24 |
14/05/22 |
14/05/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
24
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
6 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
6
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
20 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
20
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
25 |
01/05/22 |
01/05/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
25
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
21 |
30/04/22 |
30/04/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
21
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
2 |
26/04/22 |
26/04/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
2
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Vinceanna
|
3.5K |
1.0M |
19 |
23/04/22 |
23/04/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
19
|
|